Whitehawk Therapeutics Inc (WHWK) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Whitehawk Therapeutics Inc (WHWK) Earnings Overview
As of June 13, 2026, Whitehawk Therapeutics Inc (WHWK) reported trailing twelve-month net income of -$21M, reflecting +86.0% year-over-year growth. The company earned $-0.30 per diluted share over the past four quarters, with a net profit margin of -288.3%.
Looking at the long-term picture, WHWK's historical earnings data spans multiple years. The company achieved its highest annual net income of -$3M in fiscal 2020.
Whitehawk Therapeutics Inc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ACAD ($376M net income, 36.5% margin), AXSM (-$188M net income, -28.7% margin), INVA ($504M net income, 63.8% margin), WHWK has room to improve margins relative to the peer group. Compare WHWK vs ACAD →
WHWK Earnings vs Peers
Earnings metrics vs comparable public companies
WHWK Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$21M | +67.7% | -$114M | $-0.33 | -288.3% | -1601.1% |
| 2024 | -$64M | +3.2% | -$67M | $-2.36 | -245.1% | -259.6% |
| 2023 | -$66M | -8.7% | -$72M | $-2.44 | -270.0% | -295.4% |
| 2022 | -$61M | +45.0% | -$63M | $-2.69 | -397.7% | -411.9% |
| 2021 | -$110M | -3065.3% | -$111M | $-12.41 | -9829.5% | -9930.1% |
| 2020 | -$3M | +71.6% | -$3M | $-0.21 | -23.9% | -17.5% |
| 2019 | -$12M | - | -$12M | $-1.65 | -1636.2% | -1624.8% |
Download Data
Export WHWK earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in WHWK back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in WHWK be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs WHWK Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationWHWK vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowWHWK — Frequently Asked Questions
Quick answers to the most common questions about buying WHWK stock.
What is WHWK earnings per share (EPS)?
WHWK trailing twelve-month (TTM) diluted EPS is $-0.30, reflecting +86.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Whitehawk Therapeutics Inc's net income?
Whitehawk Therapeutics Inc (WHWK) trailing twelve-month net income is $-21M as of 2025. Earnings grew +86.0% year-over-year.
Is WHWK profitable?
WHWK is not currently profitable on a TTM basis, reporting a net loss of $-21M. Net margin is -288.3%. Investors should monitor for a return to profitability.
What is WHWK's earnings growth rate?
WHWK compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are WHWK's profit margins?
Whitehawk Therapeutics Inc net profit margin is -288.3%, operating margin is -1601.1%, and gross margin is +89.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -21.8%.
Is WHWK growing earnings?
Yes, WHWK earnings are accelerating — EPS growth of +86.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-21M. Earnings momentum is strengthening.
What was WHWK's best earnings year?
Whitehawk Therapeutics Inc's highest annual net income on record is $-3M, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were WHWK's earnings last quarter?
WHWK's most recent reported quarter was Q4 2025. Net income was $-23M with diluted EPS of $-0.34. For a full breakdown of all quarters, see the quarterly earnings table on this page.